Recursion Pharmaceuticals
RXRX | NASDAQ
$2.90
-$0.29 (-8.95%)
At close: Nov 16, 2026, 4:00 PM ET
$2.91
+$0.01 (+0.33%)
After-hours:
Nov 16, 2026, 7:57 PM ET
Recursion Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Key Executives
| Name | Position |
|---|---|
| Najat Khan | CEO, President & Director |
| Ben R. Taylor | Chief Financial Officer & President of Recursion UK |
| Benjamin Mabey | Chief Technology Officer |
| Nathan Hatfield | Chief Legal Officer & Corporate Secretary |
| David Hallett | Chief Scientific Officer |
| Erica Fox | Chief People and Impact Officer |
| Matthew Kinn | Chief Business Officer |
| Ryan Kelly | Chief Communications Officer |
| Sid Jain | Senior Vice President of Clinical Development & Data Science |
| Vicki L. Goodman | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | 424B5 | Filing |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 15, 2026 | 424B5 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
Recursion Pharmaceuticals
| Country | United States |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 600 |
| CEO | Najat Khan |
Contact Details
41 South Rio Grande Street Salt Lake City,
Utah 84101 United States
Stock Details
| Ticker Symbol | RXRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001601830 |
| CUSIP Number | 75629V104 |
| ISIN Number | US75629V1044 |
| SIC Code | 2836 |
Recent News
- 5 days ago / finbold.com2 healthcare stocks to turn $10 into $100 by next year
- 5 days ago / globenewswire.comRecursion to Participate in Upcoming Investor Conferences
- 13 days ago / zacks.comRXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
- 13 days ago / seekingalpha.comRecursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call Transcript
- 14 days ago / marketbeat.comWhat Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call
- 14 days ago / zacks.comRecursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
- 14 days ago / globenewswire.comRecursion Appoints Fred Hassan as Chair of the Board
- 17 days ago / zacks.comRecursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
- 19 days ago / zacks.comRecursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
- 20 days ago / zacks.comRecursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Add to Watchlist
Select watchlists to add or remove RXRX